WO2001043691A3 - Fragments and antagonists of heat shock protein 60 - Google Patents

Fragments and antagonists of heat shock protein 60 Download PDF

Info

Publication number
WO2001043691A3
WO2001043691A3 PCT/IL2000/000833 IL0000833W WO0143691A3 WO 2001043691 A3 WO2001043691 A3 WO 2001043691A3 IL 0000833 W IL0000833 W IL 0000833W WO 0143691 A3 WO0143691 A3 WO 0143691A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsp60
fragments
antagonists
pro
cells
Prior art date
Application number
PCT/IL2000/000833
Other languages
French (fr)
Other versions
WO2001043691A2 (en
Inventor
Hubert Kolb
Dana Elias
Original Assignee
Peptor Ltd
Hubert Kolb
Dana Elias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptor Ltd, Hubert Kolb, Dana Elias filed Critical Peptor Ltd
Priority to EP00981586A priority Critical patent/EP1237570A4/en
Priority to CA002394504A priority patent/CA2394504A1/en
Priority to AU18816/01A priority patent/AU784623B2/en
Priority to NZ519348A priority patent/NZ519348A/en
Priority to JP2001544632A priority patent/JP2004501061A/en
Priority to IL15011300A priority patent/IL150113A0/en
Publication of WO2001043691A2 publication Critical patent/WO2001043691A2/en
Publication of WO2001043691A3 publication Critical patent/WO2001043691A3/en
Priority to US10/172,102 priority patent/US20040022777A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

The invention identifies fragments of hsp60 which retain the capability of inducing a pro-inflammatory immune response of cells of the innate immune system. It is further disclosed the unexpectedfinding that smaller peptides derived from these fragments of hsp60 are capable of acting as antagonists of hsp60 insofar as they have the ability to reduce or even prevent the induction of a pro-inflammatory immune response by hsp60 in cells of the innate immune system. It further discloses variants, derivatives and analogs of such peptides, which are capable of acting as antagonists of hsp60 insofar as they have the ability to reduce or prevent the induction of a pro-inflammatory immune response by hsp60 in cells of the immune system. The invention also discloses pharmaceutical compositions comprising such peptide fragments or variants, derivatives and analogs thereof, and their use to prevent or ameliorate inflammatory diseases or disorders.
PCT/IL2000/000833 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60 WO2001043691A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00981586A EP1237570A4 (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
CA002394504A CA2394504A1 (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
AU18816/01A AU784623B2 (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
NZ519348A NZ519348A (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
JP2001544632A JP2004501061A (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
IL15011300A IL150113A0 (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60
US10/172,102 US20040022777A1 (en) 1999-12-15 2002-06-13 Fragments and antagonists of heat shock protein 60

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17229799P 1999-12-15 1999-12-15
EP99125035.8 1999-12-15
EP99125035 1999-12-15
US60/172,297 1999-12-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/172,102 Continuation US20040022777A1 (en) 1999-12-15 2002-06-13 Fragments and antagonists of heat shock protein 60

Publications (2)

Publication Number Publication Date
WO2001043691A2 WO2001043691A2 (en) 2001-06-21
WO2001043691A3 true WO2001043691A3 (en) 2002-01-10

Family

ID=32842929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000833 WO2001043691A2 (en) 1999-12-15 2000-12-14 Fragments and antagonists of heat shock protein 60

Country Status (7)

Country Link
EP (1) EP1237570A4 (en)
JP (1) JP2004501061A (en)
AU (1) AU784623B2 (en)
CA (1) CA2394504A1 (en)
NZ (1) NZ519348A (en)
WO (1) WO2001043691A2 (en)
ZA (1) ZA200204635B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140233A0 (en) * 2000-12-11 2002-02-10 Peptor Ltd Backbone cyclized analogs of heat shock proteins
AU2002323106A1 (en) * 2001-08-10 2003-02-24 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
EP2157101B1 (en) 2002-01-31 2014-09-24 Andromeda Bio Tech Ltd. HSP peptides and analogs for modulation of immune responses via antigen presenting cells
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
EP1758924B1 (en) * 2004-06-01 2008-12-31 Council of Scientific and Industrial Research Peptides antagonists for inhibiting heat shock protein (hsp 16.3) of mycobacterium tuberculosis
CU23504A1 (en) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
JP4283812B2 (en) * 2006-01-06 2009-06-24 財団法人工業技術研究院 Diagnostic method of myasthenia gravis and its kit
US8742068B2 (en) 2007-07-06 2014-06-03 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
WO2010033294A1 (en) 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CU23701A1 (en) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech METHOD OF TREATMENT OF INTESTINAL INFLAMMATORY DISEASES AND TYPE I DIABETES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001959A1 (en) * 1995-06-30 1997-01-23 Yeda Research And Development Co. Ltd. Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770687A (en) * 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd Immunological and oral tolerance-inducing composition and use thereof for the prevention and/or for the treatment of atherosclerosis
IL140233A0 (en) * 2000-12-11 2002-02-10 Peptor Ltd Backbone cyclized analogs of heat shock proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
WO1997001959A1 (en) * 1995-06-30 1997-01-23 Yeda Research And Development Co. Ltd. Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1237570A4 *

Also Published As

Publication number Publication date
EP1237570A2 (en) 2002-09-11
WO2001043691A2 (en) 2001-06-21
CA2394504A1 (en) 2001-06-21
ZA200204635B (en) 2004-05-26
AU1881601A (en) 2001-06-25
NZ519348A (en) 2006-04-28
EP1237570A4 (en) 2005-01-05
AU784623B2 (en) 2006-05-18
JP2004501061A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
WO2001043691A3 (en) Fragments and antagonists of heat shock protein 60
HUP0301003A2 (en) Casein derived peptides and uses thereof in therapy
CA2253636A1 (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
HK1001495A1 (en) Obesity (ob) peptides capable of modulating body weight of animals allelic variants analogs and fragments thereof derivatives nucleic acid sequences vectors hosts and the like related thereto and pharmaceutical compositions and related uses
WO2003086451A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1248645A4 (en) Novel chimeric proteins and methods for using the same
WO2002072788A3 (en) Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
EP1354598A3 (en) Therapeutic uses of BR43X2 soluble receptors
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
DK0950096T3 (en) Anti-invasive and anti-angiogenic urokinase fragments and their use
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
WO2004064717A3 (en) Cop 1 for treatment of inflammatory bowel diseases
WO2002050277A3 (en) Protein and nucleic acids encoding same
DK1095061T3 (en) Peptides based on the sequence of human lactoferring and their use
WO2000075173A3 (en) Peptide fragments of colostrinin
WO2006072946A3 (en) Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
JP2009527510A5 (en)
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
WO2002081507A3 (en) Interferon gamma polypeptide variants
AU2001249214A1 (en) Suppression of vascular disorders by mucosal administration of heat shock protein peptides
IL153557A0 (en) Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 519348

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 150113

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200204633

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000981586

Country of ref document: EP

Ref document number: 18816/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 544632

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10172102

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2394504

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000981586

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000981586

Country of ref document: EP